PA-BOOMI
9.5.2024 15:01:33 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced an enhanced version of Boomi for SAP to help accelerate the migration of SAP Business Warehouse (SAP BW) customers to SAP Datasphere. By leveraging Amazon Web Services (AWS), Boomi aims to address the critical challenge of enterprise customers who need to transition to SAP Datasphere, and unlock the full potential of their business data in a cost-effective and streamlined way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509748233/en/
Boomi to Simplify and Accelerate the Move to SAP Datasphere (Graphic: Business Wire)
Addressing a Critical Challenge in Data Migration
With mainstream support ending for SAP BW coming at the close of 2027, SAP BW customers are encouraged to migrate to SAP Datasphere, which will enable business transformation by delivering seamless, scalable access to business-critical data. However, the move to SAP Datasphere requires significant investment and substantial effort from highly-skilled individuals.
Boomi for SAP accelerates the transition to SAP Datasphere on AWS through Boomi’s low-code, integration platform. Customers can simply log into the Boomi Enterprise Platform and leverage a pre-built accelerator specifically designed to speed the migration and integration of data into SAP Datasphere on AWS.
“SAP Datasphere is SAP's foundation for a business data fabric, but many companies with earlier versions of SAP BW are overburdened with the cost-prohibitive, time-consuming, and resource-intensive process of migrating to it,” said Steve Lucas, CEO at Boomi. “This new collaboration leverages Boomi’s expertise in intelligent integration and automation, along with AWS services, to provide a lighter, faster, more cost-effective way for organizations to transition to SAP Datasphere, getting the most out of their SAP investments and their data.”
Key benefits of Boomi for SAP include:
- Avoid costly SAP BW version upgrades and the need for a staging area, resulting in time and cost savings
- The ability to select which SAP BW Queries and BW InfoProviders to move to Datasphere
- Efficient data tiering to SAP Datasphere and Amazon Redshift, a fully managed, petabyte-scale data warehouse service, enabling businesses to move less frequently used data to more affordable cloud storage tiers
- Faster integration of third-party data into SAP Datasphere at a lower cost
- Better data preparation for more efficient use of data analytics and artificial intelligence (AI)
- A smooth procurement process in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS
“The ability to aggregate diverse datasets is emerging as a critical advantage as organizations recognize the pivotal role of AI in their operations,” said Matt Aslett, director of research at Ventana Research, part of ISG. “Data preparation and integration is imperative to ensuring more efficient utilization of data analytics and AI, and the acceleration of business outcomes through data-driven decision-making.”
“Working with AWS reinforces Boomi’s commitment to delivering a practical path to enterprise analytics and AI, beginning with a robust data foundation,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “With the Boomi Enterprise Platform, organizations can achieve a more flexible, scalable, and connected ecosystem to drive innovation, future-proof their IT investments, reduce total cost of ownership, and enhance business outcomes.”
Availability
Boomi for SAP is available in AWS Marketplace, and on the Boomi Enterprise Platform.
Additional Resources
- Find Boomi in AWS Marketplace
- Explore Boomi Recipes and Accelerators for SAP in the Discover Catalog
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509748233/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom